RU2016107426A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2016107426A3 RU2016107426A3 RU2016107426A RU2016107426A RU2016107426A3 RU 2016107426 A3 RU2016107426 A3 RU 2016107426A3 RU 2016107426 A RU2016107426 A RU 2016107426A RU 2016107426 A RU2016107426 A RU 2016107426A RU 2016107426 A3 RU2016107426 A3 RU 2016107426A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL2011262 | 2013-08-02 | ||
| NL2011262 | 2013-08-02 | ||
| NL2012361 | 2014-03-04 | ||
| NL2012361 | 2014-03-04 | ||
| PCT/NL2014/050543 WO2015016718A1 (en) | 2013-08-02 | 2014-08-02 | Combining cd27 agonists and immune checkpoint inhibition for immune stimulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016107426A RU2016107426A (ru) | 2017-09-07 |
| RU2016107426A3 true RU2016107426A3 (enExample) | 2018-06-28 |
Family
ID=51494473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016107426A RU2016107426A (ru) | 2013-08-02 | 2014-08-02 | Комбинирование агонистов cd27 и ингибирование иммунных контрольных точек для стимуляции иммунитета |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20160185870A1 (enExample) |
| EP (1) | EP3027210A1 (enExample) |
| JP (1) | JP2016531907A (enExample) |
| KR (1) | KR20160037989A (enExample) |
| CN (1) | CN105682683A (enExample) |
| AU (1) | AU2014296887A1 (enExample) |
| BR (1) | BR112016001420A2 (enExample) |
| CA (1) | CA2917858A1 (enExample) |
| MX (1) | MX2016000750A (enExample) |
| RU (1) | RU2016107426A (enExample) |
| WO (1) | WO2015016718A1 (enExample) |
Families Citing this family (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011239706B2 (en) | 2010-04-13 | 2015-08-20 | Celldex Therapeutics Inc. | Antibodies that bind human CD27 and uses thereof |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| US9789182B2 (en) * | 2012-10-23 | 2017-10-17 | Bristol-Myers Squibb Company | Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer |
| WO2014071419A2 (en) | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Novel fusion molecules and uses thereof |
| AU2014207342C1 (en) | 2013-01-18 | 2019-04-04 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| EA036902B1 (ru) | 2013-09-20 | 2021-01-13 | Бристол-Майерс Сквибб Компани | Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей |
| LT3081576T (lt) | 2013-12-12 | 2019-10-25 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antikūnas, antigeną surišantis jo fragmentas ir jų medicininis pritaikomumas |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| SG11201700700YA (en) * | 2014-08-01 | 2017-02-27 | 3M Innovative Properties Co | Methods and therapeutic combinations for treating tumors |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| GB201419084D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-PD-1 antibodies |
| JP6952603B2 (ja) | 2015-02-10 | 2021-10-20 | オハイオ・ステイト・イノベーション・ファウンデーション | クラミジア活性化ｂ細胞プラットフォーム及びその方法 |
| WO2016145085A2 (en) * | 2015-03-09 | 2016-09-15 | Celldex Therapeutics, Inc. | Cd27 agonists |
| AU2016235434B2 (en) * | 2015-03-20 | 2022-02-03 | Syndax Pharmaceuticals, Inc. | Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| EP3283882B2 (en) | 2015-04-17 | 2024-10-16 | Merck Sharp & Dohme LLC | Blood-based biomarkers of tumor sensitivity to pd-1 antagonists |
| DK3291679T3 (da) | 2015-05-06 | 2022-01-17 | Snipr Tech Ltd | Ændring af mikrobielle populationer og modificering af mikrobiota |
| EP3892284B1 (en) | 2015-05-29 | 2024-05-22 | Merck Sharp & Dohme LLC | Combination of a pd-1 antagonist and a cpg-c type oligonucleotide for treating cancer |
| DK3303394T3 (da) | 2015-05-29 | 2020-07-06 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
| CN107921087A (zh) | 2015-07-16 | 2018-04-17 | 百欧肯治疗有限公司 | 治疗癌症的组合物及方法 |
| US10894044B2 (en) | 2015-09-16 | 2021-01-19 | Board Of Regents, The University Of Texas System | Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer |
| DK3356401T3 (da) * | 2015-09-30 | 2020-09-07 | Igm Biosciences Inc | Bindingsmolekyler med modificeret j-kæde |
| MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
| TWI805542B (zh) * | 2015-10-23 | 2023-06-21 | 日商坎巴斯有限公司 | 用於癌症治療之肽及擬肽與ｔ細胞活化劑及／或查核點抑制劑之組合 |
| US10149887B2 (en) * | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
| EP3364995B1 (en) * | 2015-10-23 | 2021-08-04 | Apogenix AG | Single-chain cd27-receptor agonist proteins |
| LT3370733T (lt) | 2015-11-02 | 2021-10-25 | Board Of Regents, The University Of Texas System | Cd40 aktyvinimo ir imuninės kontrolės taškų blokados būdai |
| JP6859954B2 (ja) * | 2015-11-04 | 2021-04-14 | アステラス製薬株式会社 | ジアミノヘテロ環カルボキサミド化合物を有効成分とするがん免疫治療用、及び／又は、免疫活性化用医薬組成物 |
| WO2017079746A2 (en) | 2015-11-07 | 2017-05-11 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| WO2017083337A1 (en) | 2015-11-10 | 2017-05-18 | Ohio State Innovation Foundation | Methods and compositions related to accelerated humoral affinity |
| KR20180086502A (ko) | 2015-12-16 | 2018-07-31 | 머크 샤프 앤드 돔 코포레이션 | 항-lag3 항체 및 항원-결합 단편 |
| EP4299136A3 (en) | 2015-12-16 | 2024-02-14 | Gritstone bio, Inc. | Neoantigen identification, manufacture, and use |
| KR20180089444A (ko) | 2015-12-22 | 2018-08-08 | 리제너론 파아마슈티컬스, 인크. | 암을 치료하기 위한 항-pd-1 항체와 이특이적 항-cd20/항-cd3 항체의 조합 |
| WO2017123643A1 (en) * | 2016-01-11 | 2017-07-20 | Flagship Pioneering, Inc. | Methods and compositions for modulating thymic function |
| KR102033920B1 (ko) | 2016-02-23 | 2019-10-18 | 바이오라인알엑스 리미티드 | 급성 골수성 백혈병을 치료하는 방법 |
| EP3436480A4 (en) | 2016-03-30 | 2019-11-27 | Musc Foundation for Research Development | METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION |
| WO2017184619A2 (en) | 2016-04-18 | 2017-10-26 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human cd40 and uses thereof |
| EP3449017B1 (en) | 2016-04-29 | 2021-12-22 | Board of Regents, The University of Texas System | Targeted measure of transcriptional activity related to hormone receptors |
| TWI822521B (zh) | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | 藉由投予pd-1抑制劑治療皮膚癌之方法 |
| MY195089A (en) | 2016-05-27 | 2023-01-10 | Agenus Inc | Anti-Tim-3 Antibodies and Methods of use thereof |
| GB201609811D0 (en) | 2016-06-05 | 2016-07-20 | Snipr Technologies Ltd | Methods, cells, systems, arrays, RNA and kits |
| JP7461741B2 (ja) | 2016-06-20 | 2024-04-04 | カイマブ・リミテッド | 抗ｐｄ－ｌ１およびｉｌ－２サイトカイン |
| CN109563481B (zh) | 2016-07-13 | 2024-01-05 | 俄亥俄州创新基金会 | 用于优化宿主抗原呈递和宿主抗肿瘤和抗病原体免疫的平台和方法 |
| JOP20190055A1 (ar) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | أجسام مضادة ضد cd27 |
| AU2017335732B2 (en) | 2016-09-27 | 2024-11-21 | Board Of Regents, The University Of Texas System | Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome |
| IL265800B2 (en) | 2016-10-11 | 2023-10-01 | Agenus Inc | Anti-LAG-3 antibodies and methods of using them |
| CN110072540B (zh) | 2016-10-12 | 2023-06-02 | 得克萨斯州大学系统董事会 | 用于tusc2免疫治疗的方法和组合物 |
| WO2018089423A1 (en) | 2016-11-09 | 2018-05-17 | Musc Foundation For Research Development | Cd38-nad+ regulated metabolic axis in anti-tumor immunotherapy |
| WO2018094225A1 (en) | 2016-11-17 | 2018-05-24 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 mutations |
| IL311265A (en) | 2016-12-05 | 2024-05-01 | G1 Therapeutics Inc | Preservation of immune response during chemotherapy regimens |
| PT3551660T (pt) | 2016-12-07 | 2023-11-30 | Ludwig Inst For Cancer Res Ltd | Anticorpos anti-ctla-4 e métodos de uso dos mesmos |
| EP3551226A1 (en) | 2016-12-12 | 2019-10-16 | MultiVir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
| CN110612447B (zh) | 2017-02-24 | 2024-02-06 | 德克萨斯州立大学董事会 | 用于检测早期胰腺癌的测定 |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| JP7537874B2 (ja) | 2017-05-19 | 2024-08-21 | シンダックス ファーマシューティカルズ， インコーポレイテッド | 併用療法 |
| EP3630179A2 (en) | 2017-05-30 | 2020-04-08 | Bristol-Myers Squibb Company | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody |
| PT3631454T (pt) | 2017-05-30 | 2023-11-23 | Bristol Myers Squibb Co | Tratamento de tumores positivos para lag-3 |
| US12259379B2 (en) | 2017-06-30 | 2025-03-25 | Osaka University | Method for predicting effect of tumor immunotherapy using tumor cytotoxic activity of peripheral blood T cells as index |
| WO2019040780A1 (en) | 2017-08-25 | 2019-02-28 | Five Prime Therapeutics Inc. | ANTI-B7-H4 ANTIBODIES AND METHODS OF USE |
| EP3694532B1 (en) | 2017-10-10 | 2025-02-26 | Gritstone bio, Inc. | Neoantigen identification using hotspots |
| AU2018346957B2 (en) | 2017-10-12 | 2024-08-01 | Board Of Regents, The University Of Texas System | T cell receptors for immunotherapy |
| IL274799B2 (en) | 2017-11-22 | 2025-05-01 | Gritstone Bio Inc | Reducing junction epitope presentation for neoantigens |
| US20190241660A1 (en) * | 2017-12-05 | 2019-08-08 | Intendet Services, Llc | Immune-stimulating peptides and checkpoint inhibitors, and uses thereof for treating cancer |
| AU2019226011B2 (en) | 2018-02-21 | 2025-11-27 | Five Prime Therapeutics, Inc. | B7-H4 antibody formulations |
| CN111971308A (zh) | 2018-03-02 | 2020-11-20 | 戊瑞治疗有限公司 | B7-h4抗体及其使用方法 |
| AU2019322487B2 (en) | 2018-03-19 | 2024-04-18 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer |
| KR20210006344A (ko) | 2018-03-25 | 2021-01-18 | 에스엔아이피알 바이옴 에이피에스. | 미생물 감염의 치료 및 예방 |
| US10760075B2 (en) | 2018-04-30 | 2020-09-01 | Snipr Biome Aps | Treating and preventing microbial infections |
| CA3094108A1 (en) | 2018-03-27 | 2019-10-03 | Board Of Regents, The University Of Texas Systems | Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations |
| WO2019191429A2 (en) | 2018-03-28 | 2019-10-03 | Board Of Regents, The University Of Texas System | Identification of epigenetic alterations in dna isolated from exosomes |
| JP7466459B2 (ja) | 2018-04-17 | 2024-04-12 | セルデックス セラピューティクス インコーポレイテッド | 抗ｃｄ２７および抗ｐｄ－ｌ１抗体ならびに二重特異性構築物 |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| WO2020106621A1 (en) | 2018-11-19 | 2020-05-28 | Board Of Regents, The University Of Texas System | A modular, polycistronic vector for car and tcr transduction |
| EA202191463A1 (ru) | 2018-11-28 | 2021-10-13 | Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем | Мультиплексное редактирование генома иммунных клеток для повышения функциональности и устойчивости к подавляющей среде |
| CN113316455A (zh) | 2018-11-29 | 2021-08-27 | 得克萨斯大学体系董事会 | 用于离体扩增自然杀伤细胞的方法及其用途 |
| WO2020136879A1 (ja) * | 2018-12-28 | 2020-07-02 | 国立大学法人大阪大学 | 悪性腫瘍を治療するための免疫療法剤の有用性の提示方法及び悪性腫瘍を治療するための免疫療法剤 |
| CN120468425A (zh) * | 2019-01-30 | 2025-08-12 | 国家医疗保健研究所 | 用于鉴定患有癌症的受试者是否将获得对免疫检查点抑制剂的应答的方法和组合物 |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| US12492380B2 (en) | 2019-05-09 | 2025-12-09 | FUJIFILM Cellular Dynamics, Inc. | Methods for the production of hepatocytes |
| JP2022532766A (ja) | 2019-05-17 | 2022-07-19 | キャンサー プリベンション ファーマシューティカルズ，インコーポレイテッド | 家族性腺腫性ポリポーシスを処置するための方法 |
| WO2021087458A2 (en) | 2019-11-02 | 2021-05-06 | Board Of Regents, The University Of Texas System | Targeting nonsense-mediated decay to activate p53 pathway for the treatment of cancer |
| TWI895295B (zh) | 2019-11-12 | 2025-09-01 | 美商方得生醫療公司 | 偵測編碼新生抗原之融合基因之方法 |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| US12251449B2 (en) | 2019-12-19 | 2025-03-18 | William Marsh Rice University | Synthetic multidomain peptide biomaterials that inhibit inducible nitric oxide synthase |
| WO2021141977A1 (en) | 2020-01-07 | 2021-07-15 | Board Of Regents, The University Of Texas System | Improved human methyl thioadenosine/adenosine depleting enzyme variants for cancer therapy |
| JP2023513006A (ja) | 2020-01-29 | 2023-03-30 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｎｒｇ１融合体を有するがんの治療のためのｅｇｆｒ／ｈｅｒ２チロシンキナーゼインヒビターおよび／またはｈｅｒ２／ｈｅｒ３抗体の使用 |
| EP4096789A4 (en) | 2020-01-29 | 2023-10-11 | Board of Regents, The University of Texas System | USE OF POZIOTINIB TO TREAT CANCER WITH NRG1 FUSIONS |
| EP4107173A1 (en) | 2020-02-17 | 2022-12-28 | Board of Regents, The University of Texas System | Methods for expansion of tumor infiltrating lymphocytes and use thereof |
| US20230114276A1 (en) * | 2020-03-06 | 2023-04-13 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Modulating anti-tumor immunity |
| EP4153301A2 (en) | 2020-05-21 | 2023-03-29 | Board of Regents, The University of Texas System | T cell receptors with vgll1 specificity and uses thereof |
| WO2021247836A1 (en) | 2020-06-03 | 2021-12-09 | Board Of Regents, The University Of Texas System | Methods for targeting shp-2 to overcome resistance |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| EP4172323A1 (en) | 2020-06-29 | 2023-05-03 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| WO2022104109A1 (en) | 2020-11-13 | 2022-05-19 | Catamaran Bio, Inc. | Genetically modified natural killer cells and methods of use thereof |
| AU2021388155A1 (en) | 2020-11-25 | 2023-06-15 | Catamaran Bio, Inc. | Cellular therapeutics engineered with signal modulators and methods of use thereof |
| CA3205538A1 (en) | 2021-01-19 | 2022-07-28 | Han XIAO | Bone-specific delivery of polypeptides |
| US20220325287A1 (en) | 2021-03-31 | 2022-10-13 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| EP4363059A1 (en) | 2021-06-29 | 2024-05-08 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| AU2022324040A1 (en) | 2021-08-04 | 2024-02-22 | The Regents Of The University Of Colorado, A Body Corporate | Lat activating chimeric antigen receptor t cells and methods of use thereof |
| CN118369419A (zh) | 2021-10-05 | 2024-07-19 | 赛托维亚治疗有限责任公司 | 自然杀伤细胞及其使用方法 |
| KR20240099161A (ko) | 2021-10-20 | 2024-06-28 | 다케다 야쿠힌 고교 가부시키가이샤 | Bcma를 표적화하는 조성물 및 이의 사용 방법 |
| WO2023076880A1 (en) | 2021-10-25 | 2023-05-04 | Board Of Regents, The University Of Texas System | Foxo1-targeted therapy for the treatment of cancer |
| WO2023172514A1 (en) | 2022-03-07 | 2023-09-14 | Catamaran Bio, Inc. | Engineered immune cell therapeutics targeted to her2 and methods of use thereof |
| EP4514382A1 (en) | 2022-04-28 | 2025-03-05 | Musc Foundation for Research Development | Chimeric antigen receptor modified regulatory t cells for treating cancer |
| WO2023220083A1 (en) | 2022-05-09 | 2023-11-16 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and methods of use for treating proliferative disorders |
| CN119451985A (zh) | 2022-05-12 | 2025-02-14 | 健玛保 | 在组合疗法中能够结合cd27的结合剂 |
| GB202209518D0 (en) | 2022-06-29 | 2022-08-10 | Snipr Biome Aps | Treating & preventing E coli infections |
| EP4598946A1 (en) | 2022-10-05 | 2025-08-13 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| WO2025217275A2 (en) | 2024-04-10 | 2025-10-16 | Flagship Pioneering Innovations Vii, Llc | Immune cell targeted compositions and related methods |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5229289A (en) | 1988-03-11 | 1993-07-20 | The Biomembrane Institute | Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human and with synthetic carbohydrate-carrier conjugates |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE297465T1 (de) | 1991-11-25 | 2005-06-15 | Enzon Inc | Verfahren zur herstellung von multivalenten antigenbindenden proteinen |
| US20030035790A1 (en) | 1999-01-15 | 2003-02-20 | Shu-Hsia Chen | Combination therapy for the prevention or treatment of cancer, inflammatory disorders or infectious diseases in a subject |
| US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
| US20070134247A9 (en) | 2002-04-12 | 2007-06-14 | Ramot At Tel Aviv University Ltd. | Prevention of brain inflammation as a result of induced autoimmune response |
| EP1578419A4 (en) | 2002-12-30 | 2008-11-12 | 3M Innovative Properties Co | IMMUNOSTIMULATING COMBINATIONS |
| US7728114B2 (en) | 2004-06-03 | 2010-06-01 | Novimmune S.A. | Anti-CD3 antibodies and methods of use thereof |
| US20110142858A1 (en) | 2004-06-07 | 2011-06-16 | Ramot At Tel Aviv University Ltd. | Method of Passsive Immunization Against Disease or Disorder Charcterized by Amyloid Aggregation with Diminished Risk of Neuroinflammation |
| AU2005259221B2 (en) | 2004-07-01 | 2011-02-10 | Innate Pharma | Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use |
| WO2006005770A2 (en) | 2004-07-15 | 2006-01-19 | Technische Universität Wien | Method for the detection of fusarium graminearum |
| CA2970873C (en) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| EP3910065B8 (en) | 2006-09-08 | 2025-09-17 | AbbVie Manufacturing Management Unlimited Company | Interleukin -13 binding proteins |
| GB0620894D0 (en) * | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| SI2170959T1 (sl) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Protitelesa proti receptorjem pd-1 za humano programirano smrt |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| CA2729567C (en) | 2008-06-30 | 2018-04-24 | Kyowa Hakko Kirin Co., Ltd. | Anti-cd27 antibody |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| FI4209510T3 (fi) | 2008-12-09 | 2024-03-22 | Hoffmann La Roche | Anti-PD-L1-vasta-aineita ja niiden käyttö T-solutoiminnan tehostamiseksi |
| EA201270228A1 (ru) | 2009-07-31 | 2012-09-28 | Медарекс, Инк. | Полноценные человеческие антитела к btla |
| JP2013503204A (ja) | 2009-08-31 | 2013-01-31 | アンプリミューン， インコーポレイテッド | Ｂ７−ｈ４融合タンパク質およびその使用方法 |
| LT3279215T (lt) | 2009-11-24 | 2020-04-10 | Medimmune Limited | Tiksliniai surišantys agentai prieš b7-h1 |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| AU2013203270B2 (en) * | 2010-04-13 | 2016-05-19 | Celldex Therapeutics Inc. | Antibodies that bind human CD27 and uses thereof |
| AU2011239706B2 (en) | 2010-04-13 | 2015-08-20 | Celldex Therapeutics Inc. | Antibodies that bind human CD27 and uses thereof |
| CA2804550C (en) | 2010-07-09 | 2021-01-05 | Bionovion Holding B.V. | Agonistic antibody to cd27 |
| PL2691112T3 (pl) | 2011-03-31 | 2018-09-28 | Merck Sharp & Dohme Corp. | Stabilne preparaty przeciwciał przeciw ludzkiemu receptorowi programowanej śmierci pd-1 i terapie powiązane |
| US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
| AU2012296613B2 (en) | 2011-08-15 | 2016-05-12 | Amplimmune, Inc. | Anti-B7-H4 antibodies and their uses |
| ES2861435T3 (es) | 2011-11-03 | 2021-10-06 | Univ Pennsylvania | Composiciones específicas de B7-H4 aisladas y métodos de uso de las mismas |
| AR091649A1 (es) * | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| ES2901712T3 (es) | 2012-08-16 | 2022-03-23 | Novartis Ag | Combinación de un inhibidor de pi3k y un inhibidor de c-met. |
| TWI693232B (zh) * | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
-
2014
- 2014-08-02 BR BR112016001420A patent/BR112016001420A2/pt not_active IP Right Cessation
- 2014-08-02 AU AU2014296887A patent/AU2014296887A1/en not_active Abandoned
- 2014-08-02 MX MX2016000750A patent/MX2016000750A/es unknown
- 2014-08-02 CA CA2917858A patent/CA2917858A1/en not_active Abandoned
- 2014-08-02 CN CN201480043800.XA patent/CN105682683A/zh active Pending
- 2014-08-02 KR KR1020167005057A patent/KR20160037989A/ko not_active Withdrawn
- 2014-08-02 JP JP2016531574A patent/JP2016531907A/ja active Pending
- 2014-08-02 EP EP14761706.2A patent/EP3027210A1/en active Pending
- 2014-08-02 RU RU2016107426A patent/RU2016107426A/ru not_active Application Discontinuation
- 2014-08-02 WO PCT/NL2014/050543 patent/WO2015016718A1/en not_active Ceased
-
2016
- 2016-01-27 US US15/007,345 patent/US20160185870A1/en not_active Abandoned
-
2019
- 2019-01-16 US US16/249,404 patent/US12168693B2/en active Active
-
2024
- 2024-11-05 US US18/938,190 patent/US20250179206A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20160185870A1 (en) | 2016-06-30 |
| MX2016000750A (es) | 2016-08-05 |
| AU2014296887A1 (en) | 2016-01-28 |
| US20190135933A1 (en) | 2019-05-09 |
| EP3027210A1 (en) | 2016-06-08 |
| US12168693B2 (en) | 2024-12-17 |
| US20250179206A1 (en) | 2025-06-05 |
| BR112016001420A2 (pt) | 2018-01-23 |
| WO2015016718A1 (en) | 2015-02-05 |
| CN105682683A (zh) | 2016-06-15 |
| KR20160037989A (ko) | 2016-04-06 |
| JP2016531907A (ja) | 2016-10-13 |
| CA2917858A1 (en) | 2015-02-05 |
| RU2016107426A (ru) | 2017-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR134186A2 (es) | Un anticuerpo anti-csf-1r, un proceso para producirlo, una composición farmacéutica que lo comprende, una secuencia de adn aislado, un vector de expresión o clonación y una célula hospedadora | |
| RU2016107426A3 (enExample) | ||
| BR112015007533A2 (enExample) | ||
| BR112016000699A2 (enExample) | ||
| BR102016010778A2 (enExample) | ||
| BR112014018502A2 (enExample) | ||
| BR112014019326A2 (enExample) | ||
| BR112014018516A2 (enExample) | ||
| BR112014018480A2 (enExample) | ||
| BR112014020341A2 (enExample) | ||
| BR112014017855A2 (enExample) | ||
| BR112014017765A2 (enExample) | ||
| BR112016001899A2 (enExample) | ||
| BR112014021878A2 (enExample) | ||
| BR112015016977A2 (enExample) | ||
| BR112016000192A2 (enExample) | ||
| BR112014018468A2 (enExample) | ||
| BR112014017901A2 (enExample) | ||
| BR112014019204A2 (enExample) | ||
| BR112014018207A2 (enExample) | ||
| BR112014018578A2 (enExample) | ||
| BR112014018483A2 (enExample) | ||
| BR112014017794A2 (enExample) | ||
| BR112014024039A2 (enExample) | ||
| BR112014018353A2 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20190211 |